Cargando…

CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression

OBJECTIVE: Cytochrome P450 (CYP) enzymatic activity, which is influenced by CYP genetic polymorphism, is known to affect the inter-individual variation in the efficacy and tolerability of antidepressants in major depressive disorder (MDD). Escitalopram is metabolized by CYP2D6, and recent studies ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Kyu-Man, Chang, Hun Soo, Choi, In-Kwang, Ham, Byung-Joo, Lee, Min-Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Neuropsychiatric Association 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843022/ https://www.ncbi.nlm.nih.gov/pubmed/24302953 http://dx.doi.org/10.4306/pi.2013.10.3.286

Ejemplares similares

CYP2C19 polymorphisms and outcomes of Escitalopram treatment in Brazilians with major depression
por: Bernini de Brito, Rodrigo, et al.
Publicado: (2020)

Effects of a Polymorphism of the Neuronal Amino Acid Transporter SLC6A15 Gene on Structural Integrity of White Matter Tracts in Major Depressive Disorder
por: Choi, Sunyoung, et al.
Publicado: (2016)

ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression
por: Singh, A B, et al.
Publicado: (2012)

Reproducibility of the Efficacy of Escitalopram in Patients with Major Depression Who Had Previously Remitted with Escitalopram
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Paroxetine versus Venlafaxine and Escitalopram in Korean Patients with Major Depressive Disorder: A Randomized, Rater-blinded, Six-week Study
por: Woo, Young Sup, et al.
Publicado: (2017)

Comparative efficacy of escitalopram in the treatment of major depressive disorder
por: Ali, Mazen K, et al.
Publicado: (2011)

Regional cortical thinning of the orbitofrontal cortex in medication-naïve female patients with major depressive disorder is not associated with MAOA-uVNTR polymorphism
por: Won, Eunsoo, et al.
Publicado: (2016)

Efficacy and safety of generic escitalopram (Lexacure(®)) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study
por: Jeong, Jong-Hyun, et al.
Publicado: (2015)

Influence of FKBP5 polymorphism and DNA methylation on structural changes of the brain in major depressive disorder
por: Han, Kyu-Man, et al.
Publicado: (2017)

Association between Glucocorticoid Receptor Methylation and Hippocampal Subfields in Major Depressive Disorder
por: Na, Kyoung-Sae, et al.
Publicado: (2014)

Effect of Escitalopram on White Blood Cells in Patients With Major Depression
por: Canan, Fatih, et al.
Publicado: (2009)

Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy
por: Mencacci, Claudio, et al.
Publicado: (2013)

PS85. Efficacy and Safety of Generic Escitalopram (Lexacure) in Patients with Major Depressive Disorder: A 6-week, Multi-center, Randomized, Rater-blinded, Escitalopram-comparative, Non-inferiority Study
por: Jeong, Jong-Hyun, et al.
Publicado: (2016)

No Association between Serotonin Receptor 2C-759C/T Polymorphism and Weight Change or Treatment Response to Mirtazapine in Korean Depressive Patients
por: Lee, Hwa-Young, et al.
Publicado: (2013)

ARPNet: Antidepressant Response Prediction Network for Major Depressive Disorder
por: Chang, Buru, et al.
Publicado: (2019)

Reduced Sulcal Depth in Central Sulcus of Major Depressive Disorder
por: Shin, Seung-Joon, et al.
Publicado: (2022)

The Impact of the CYP2D6 and CYP1A2 Gene Polymorphisms on Response to Duloxetine in Patients with Major Depression
por: Maciaszek, Julian, et al.
Publicado: (2023)

Escitalopram—translating molecular properties into clinical benefit: reviewing the evidence in major depression
por: Leonard, Brian, et al.
Publicado: (2010)

Alterations in the Occipital Cortex of Drug-Naïve Adults With Major Depressive Disorder: A Surface-Based Analysis of Surface Area and Cortical Thickness
por: Lee, Jee Soo, et al.
Publicado: (2021)

The Indirect Effect of Prefrontal Gray Matter Volume on Suicide Attempts among Individuals with Major Depressive Disorder
por: Kang, June, et al.
Publicado: (2022)

3D-QSAR Design of New Escitalopram Derivatives for the Treatment of Major Depressive Disorders
por: Avram, Speranta, et al.
Publicado: (2010)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi, Taro, et al.
Publicado: (2017)

An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus Escitalopram in Major Depression
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2022)

Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders
por: Aldrich, Stacey L., et al.
Publicado: (2019)

A Study on CYP2C19 and CYP2D6 Polymorphic Effects on Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Koreans
por: Ryu, S, et al.
Publicado: (2017)

Association between Plasma Metabolic Profiles of the Antidepressant Escitalopram and Clinical Response in Subjects with Depression
por: Bandu, Raju, et al.
Publicado: (2023)

Safety and Effectiveness of Desvenlafaxine in Korean Patients with Major Depressive Disorder: A 6-month Postmarketing Surveillance Study
por: Roh, Sungwon, et al.
Publicado: (2022)

Depression in Acromegaly Treated with Escitalopram and Cognitive Therapy
por: De Sousa, Avinash
Publicado: (2009)

Clinical efficacy of Vortioxetine and escitalopram in the treatment of depression
por: Shao, Shichuan, et al.
Publicado: (2022)

Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability
por: Kirino, Eiji
Publicado: (2012)

Comparing the Effects of Bupropion and Escitalopram on Excessive Internet Game Play in Patients with Major Depressive Disorder
por: Nam, Beomwoo, et al.
Publicado: (2017)

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
por: Maneeton, Benchalak, et al.
Publicado: (2018)

Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression
por: MahmoudianDehkordi, Siamak, et al.
Publicado: (2021)

Fabrication and Characterization of Fast-Dissolving Films Containing Escitalopram/Quetiapine for the Treatment of Major Depressive Disorder
por: Alkahtani, Manal E., et al.
Publicado: (2021)

Escitalopram-induced akathisia in a patient with major depressive disorder: A rare case report
por: Arshad, Hareem, et al.
Publicado: (2022)

Tissue-Specific Oxysterols as Predictors of Antidepressant (Escitalopram) Treatment Response in Patients With Major Depressive Disorder
por: Sun, Zuoli, et al.
Publicado: (2023)

Association of DNA Methylation of the NLRP3 Gene with Changes in Cortical Thickness in Major Depressive Disorder
por: Han, Kyu-Man, et al.
Publicado: (2022)

How Inflammation Affects the Brain in Depression: A Review of Functional and Structural MRI Studies
por: Han, Kyu-Man, et al.
Publicado: (2021)

The association between substance P and white matter integrity in medication-naive patients with major depressive disorder
por: Won, Eunsoo, et al.
Publicado: (2017)

Childhood Sexual Abuse and Cortical Thinning in Adults With Major Depressive Disorder
por: Kim, Jinyi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d4gdtao7e83hvvuv8s52to9594